Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42 ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...

GSK buys US-based rare cancer treatment developer for up to £1bn - The acquisition of IDRx will help GSK target a ‘major gap ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...

After pharma and biopharma biggies such as Amgen, Sanofi, Novartis, Bristol Myers Squibb, and Zoetis, the city is now learnt to be on the radar of pharma giants such as Eli Lilly, GSK, and Merck.

Dec 20 (Reuters) - GSK (GSK.L), opens new tab said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in ...

(RTTNews) - GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary ...

Teva Pharmaceutical Industries Ltd. ADR 1.06% $24.61B ...